Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2815MR)

This product GTTS-WQ2815MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2815MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4354MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ1071MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ8148MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ10945MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ3013MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ15888MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ4887MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ13118MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW